Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs AV-GBM-1 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors AiVita Biomedical
- 09 Mar 2018 Planned End Date changed from 1 Feb 2025 to 1 Apr 2023.
- 09 Mar 2018 Planned primary completion date changed from 1 Feb 2023 to 1 Oct 2020.
- 09 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.